West Pharmaceutical Services (NYSE:WST) Shares Gap Up on Better-Than-Expected Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) shares gapped up prior to trading on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $274.41, but opened at $308.01. West Pharmaceutical Services shares last traded at $314.2320, with a volume of 287,682 shares traded.

The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.During the same quarter last year, the firm posted $1.45 earnings per share. The company’s revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio is 12.96%.

West Pharmaceutical Services declared that its Board of Directors has authorized a stock buyback program on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 5.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q1 earnings beat — West reported $2.13 EPS vs. the $1.68 consensus and vs. $1.45 a year ago, signaling accelerating profitability and margin strength. West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: Raised FY‑2026 guidance — Management now targets $8.40–$8.75 EPS and $3.3–$3.4B revenue (above consensus), lifting full‑year profit and revenue outlook on sustained demand. West Pharma lifts 2026 profit forecast on strong demand for medical equipment
• Positive Sentiment: Stronger near‑term guidance — Q2 EPS guidance of $2.05–$2.12 and revenue guidance of $830–$850M top street estimates, supporting the thesis of continued demand for high‑value injectable solutions. West Reports First-Quarter 2026 Results
• Neutral Sentiment: Driver detail and investor materials — Management cited strong demand for proprietary products (syringes, cartridges) and provided a press release and slide deck for additional detail, which helps transparency but doesn’t add new guidance beyond the raise. View Press Release
• Neutral Sentiment: Analyst context — Pre‑earnings coverage had flagged GLP‑1 and other high‑value product momentum as a potential catalyst; the quarter validated that narrative but raises expectations going forward. WST Likely to Beat Q1 Earnings Estimates: How to Play the Stock?
• Negative Sentiment: Valuation & execution risk — The stock trades at a rich multiple (high P/E and PEG vs. long‑term growth), so the upside is contingent on sustaining the stronger growth; any future miss after guidance raises could pressure the share price.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on WST shares. UBS Group reiterated a “buy” rating and issued a $340.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th. Evercore decreased their target price on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $295.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and a consensus price target of $315.67.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Norges Bank acquired a new position in shares of West Pharmaceutical Services in the fourth quarter worth $272,041,000. Generation Investment Management LLP boosted its position in West Pharmaceutical Services by 60.0% during the fourth quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock valued at $429,733,000 after purchasing an additional 585,855 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in West Pharmaceutical Services by 22.2% in the third quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier’s stock valued at $726,895,000 after purchasing an additional 503,601 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in West Pharmaceutical Services by 67.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock worth $323,280,000 after purchasing an additional 473,547 shares during the last quarter. Finally, Steadfast Capital Management LP acquired a new position in West Pharmaceutical Services in the 3rd quarter worth about $123,667,000. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Price Performance

The stock has a 50 day moving average price of $250.67 and a two-hundred day moving average price of $261.77. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02. The company has a market capitalization of $22.83 billion, a PE ratio of 46.46, a P/E/G ratio of 2.92 and a beta of 1.15.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.